Business Wire

XPRIZE

31.5.2019 21:28:12 CEST | Business Wire | Press release

Share
Winners Announced in $7M Shell Ocean Discovery XPRIZE for Advancements in Autonomous Ocean Exploration

Today, XPRIZE , the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, has announced winners in the $7M Shell Ocean Discovery XPRIZE , a global competition to advance ocean technologies for rapid, unmanned and high-resolution ocean exploration and discovery.

The results were revealed at an awards ceremony hosted at the world-renowned Oceanographic Museum of Monaco, part of the Oceanographic Institute, Prince Albert I of Monaco Foundation. The grand prize winner, receiving a total of $4M, was GEBCO-NF Alumni , an international team based in the United States, while KUROSHIO , from Japan, claimed $1M as the runner-up:

  • GEBCO-NF (International) – Led by Rochelle Wigley, Ph.D. and Yulia Zarayskaya, Ph.D., the 14-nation team integrated existing technologies and ocean-mapping experience with a robust and low-cost unmanned surface vessel, the SeaKIT, along with a novel cloud-based data processing system that allows for rapid seabed visualization, to contribute towards comprehensive mapping of the ocean floor by 2030.
  • KUROSHIO   (Yokosuka, Japan) – Led by Takeshi Nakatani, Ph.D., the team integrated technologies from their partners to create a surface vessel and software platform that can operate with different autonomous underwater vessels, which increases the versatility of their technology.

The $1M National Oceanic and Atmospheric Administration (NOAA) Bonus Prize for teams to develop technology that could detect a chemical or biological signal underwater and autonomously track it to its source was split between junior high school team Ocean Quest from San Jose, California, claiming $800K as the winner, and Tampa Deep Sea Xplorers , from Florida, taking $200K as runner-up.

“Currently, more than 80 percent of the world’s ocean is unmapped, and I'm proud to have worked alongside the people who will change this as a part of this XPRIZE,” said Executive Director of the Ocean Discovery XPRIZE, Jyotika Virmani, Ph.D. “Our vision is that these new technologies will enable the discovery of new ocean species, underwater resources, geological features, and safer methods of exploring the deep sea, while illuminating the mysteries of the deep and discovering what has remained unknown since the dawn of time.”

Additionally, the judges unanimously recommended a $200K “Moonshot Award” for Team Tao from the United Kingdom for its unique approach to seafloor mapping, even though they did not meet the criteria of the competition.

“The Ocean Discovery XPRIZE teams' accomplishments are a true reflection of XPRIZE’s core belief that incentivizing the crowd will drive innovation and investment, leading to a massive shift in the state of the market,” said Anousheh Ansari, CEO of XPRIZE. “It is an honor to celebrate the winning teams GEBCO-NF Alumni, KUROSHIO, Ocean Quest, Tampa Deep Sea Xplorers, as well as Team Tao for their unprecedented, radical approach. We look forward to watching these pioneers shape the future of ocean exploration and discovery.”

To determine winners, the panel of independent judges reviewed data from field testing conducted in Kalamata, Greece and Ponce, Puerto Rico. In Kalamata, teams had up to 24 hours to map at least 250 km2 of the ocean seafloor at 5m horizontal resolution or higher. The gold-standard high-resolution baseline maps, against which the team maps were judged, were provided by Ocean Infinity and Fugro, while Esri, the global leader in geographic information system (GIS) software and geodatabase management, donated its award-winning ArcGIS Online platform for the teams and judges to use.

“At Shell, we are firm believers in the power of ideas and the value of collaboration to solve big problems,” said Martin Stauble, Shell’s Vice President Exploration North America and Brazil. “We are proud to be part of the Shell Ocean Discovery XPRIZE. This prize energized teams from across the globe and stimulated innovation, technology and learning, all in support of providing data for a better understanding of our oceans. We hope that the XPRIZE results will be a catalyst to create a step-change in the speed and quality of data that companies, research institutes and society can use.”

As part of the total $7M prize purse, four teams opted to compete for the $1M NOAA Bonus Prize. In a field test in Ponce, Puerto Rico, teams needed to demonstrate that their technology can “sniff out” a specified object in the ocean by first detecting and then tracing a biological or chemical signal to its source. The judges determined that no single team was able to trace the signal to its source in the timeframe allowed, so the prize was divided among the two teams that came the closest.

Last year, nine finalist teams were awarded an equal share of the first $1M of the $7M prize purse, in recognition of their progress-to-date and to support the teams’ continued technological development.

“NOAA is proud to support this important competition that is accelerating the development of new unmanned tools capable of tracking chemical and biological signals in our ocean,” said Neil Jacobs, Ph.D., acting NOAA administrator. “The cutting-edge technologies that have emerged as a result of the NOAA Bonus Prize will help fuel a growing Blue Economy and inspire future innovation.”

As part of its post-prize impact work, XPRIZE announced a partnership with Seabed 2030, a collaborative project between The Nippon Foundation and The General Bathymetric Chart of the Oceans (GEBCO) to inspire the complete mapping of the world’s ocean by 2030 and to compile all bathymetric data into the freely-available GEBCO Ocean Map.

Additionally, and in anticipation of World Oceans Day on June 8th, XPRIZE will launch a science fiction ocean anthology featuring 19 original short stories and artwork set in a future when technology has helped unlock the secrets of the world’s oceans.

For more information, visit oceandiscovery.xprize.org .

About XPRIZE

XPRIZE designs and operates multi-million-dollar, global competitions to incentivize the development of technological breakthroughs that accelerate humanity toward a better future. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE. For more information, visit xprize.org .

About Royal Dutch Shell

Shell has been a technology pioneer for more than 100 years, and has come up with many industry-transforming “firsts” to deliver energy its customers and partners need. Since 2007, Shell has spent more than $1 billion annually on research and development. In 2014, our research and development expenditures were $1.2 billion. Shell’s technical and engineering staff amount to more than 43,000.

Shell companies have operations in more than 70 countries and territories with businesses including oil and gas exploration and production; production and marketing of liquefied natural gas and gas to liquids; manufacturing, marketing and shipping of oil products and chemicals and renewable energy projects. Royal Dutch Shell plc is incorporated in England and Wales, has its headquarters in The Hague and is listed on the London, Amsterdam, and New York stock exchanges. For further information, visit www.shell.com .

About National Oceanic and Atmospheric Administration (NOAA)

The National Oceanic and Atmospheric Administration (NOAA) is a science-based federal agency within the Department of Commerce with regulatory, operational and information service responsibilities with a presence in every state and U.S. territories. NOAA's mission is to understand and predict changes in the Earth's environment, from the depths of the ocean to the surface of the sun, and to conserve and manage coastal and marine resources. For more information, visit www.noaa.gov .

Contact:

Eric Desatnik & Katherine Schelbert 310.741.4880 / eric@xprize.org katherine.schelbert@xprize.org

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye